

Table 1. Guide to Contraindications and Precautions to Commonly Used Vaccines in Children and Teens^{1,*}

Vaccine	Contraindications	Precautions
Hepatitis B (HepB)	<ul style="list-style-type: none"> • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component • Hypersensitivity to yeast 	<ul style="list-style-type: none"> • Moderate or severe acute illness with or without fever • Infant weighing less than 2000 grams (4 lbs, 6.4 oz)²
Rotavirus (RV5 [RotaTeq], RV1 [Rotarix])	<ul style="list-style-type: none"> • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component • Severe combined immunodeficiency (SCID) • History of intussusception 	<ul style="list-style-type: none"> • Moderate or severe acute illness with or without fever • Altered immunocompetence other than SCID • Chronic gastrointestinal disease³ • Spina bifida or bladder exstrophy³
Diphtheria, tetanus, pertussis (DTaP) Tetanus, diphtheria, pertussis (Tdap) Tetanus, diphtheria (DT, Td)	<ul style="list-style-type: none"> • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component • For pertussis-containing vaccines: encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of a previous dose of DTP or DTaP (for DTaP); or of previous dose of DTP, DTaP, or Tdap (for Tdap) 	<ul style="list-style-type: none"> • Moderate or severe acute illness with or without fever • Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of tetanus toxoid-containing vaccine • History of Arthus-type hypersensitivity reactions after a previous dose of tetanus or diphtheria toxoid-containing vaccine (including MenACWY); defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid containing vaccine • For pertussis-containing vaccines: progressive or unstable neurologic disorder (including infantile spasms for DTaP), uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized <p>For DTaP only:</p> <ul style="list-style-type: none"> • Temperature of 105° F or higher (40.5° C or higher) within 48 hours after vaccination with a previous dose of DTP/DTaP • Collapse or shock-like state (i.e., hypotonic hyporesponsive episode) within 48 hours after receiving a previous dose of DTP/DTaP • Seizure within 3 days after receiving a previous dose of DTP/DTaP • Persistent, inconsolable crying lasting 3 or more hours within 48 hours after receiving a previous dose of DTP/DTaP
Haemophilus influenzae type b (Hib)	<ul style="list-style-type: none"> • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component • Age younger than 6 weeks 	<ul style="list-style-type: none"> • Moderate or severe acute illness with or without fever
Inactivated poliovirus vaccine (IPV)	<ul style="list-style-type: none"> • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component 	<ul style="list-style-type: none"> • Moderate or severe acute illness with or without fever • Pregnancy
Pneumococcal (PCV13 or PPSV23)	<ul style="list-style-type: none"> • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component (including, for PCV13, to any diphtheria toxoid-containing vaccine) 	<ul style="list-style-type: none"> • Moderate or severe acute illness with or without fever
Measles, mumps, rubella (MMR)⁴	<ul style="list-style-type: none"> • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component • Severe immunodeficiency (e.g., hematologic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy⁵), or persons with human immunodeficiency virus [HIV] infection who are severely immunocompromised⁶ • Pregnancy 	<ul style="list-style-type: none"> • Moderate or severe acute illness with or without fever • Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product)⁷ • History of thrombocytopenia or thrombocytopenic purpura • Need for tuberculin skin testing⁸
Varicella (Var)⁴	<ul style="list-style-type: none"> • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component • Severe immunodeficiency (e.g., hematologic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy⁵), or persons with HIV infection who are severely immunocompromised⁶ • Pregnancy 	<ul style="list-style-type: none"> • Moderate or severe acute illness with or without fever • Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product)⁷ • Receipt of specific antivirals (i.e., acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination; avoid use of these antiviral drugs for 14 days after vaccination.

(continued)